<DOC>
	<DOCNO>NCT01925092</DOCNO>
	<brief_summary>Study objectives obtain safety , pharmacokinetic , pharmacodynamic data effect mifepristone glucose metabolism , body weight growth-hormone-IGF child refractory Cushing 's disease .</brief_summary>
	<brief_title>Mifepristone Children With Refractory Cushing 's Disease</brief_title>
	<detailed_description>The study do examine effect medication call mifepristone child Cushing 's disease . Since child 's body may absorb use mifepristone different way adult , important information amount mifepristone give child happen . Mifepristone FDA approve use adult Cushing 's syndrome , important learn mifepristone improve symptom sign Cushing 's disease child . The study limit child Cushing 's syndrome due pituitary tumor ( Cushing 's disease ) enroll child Cushing 's syndrome due cause . The study investigate child 's body absorb process mifepristone , work child effect use sugar body , child 's weight growth hormone . An important part study evaluate side effect mifepristone child .</detailed_description>
	<mesh_term>Pituitary ACTH Hypersecretion</mesh_term>
	<mesh_term>ACTH-Secreting Pituitary Adenoma</mesh_term>
	<mesh_term>Mifepristone</mesh_term>
	<criteria>Males females 617 year informed consent Active Cushing 's disease demonstrate follow : 24 hour Urinary Free Cortisol great upper limit normal age two urine collection screen midnight serum cortisol &gt; 4.4 mcg/dL ( mean two determination single day 2330 2400 screen ) Previous transsphenoidal surgery ( TSS ) ACTH secrete pituitary tumor least 3 month prior screen Increased body weight define BMI Zscore 1.5 Able provide consent/assent Able swallow study drug tablet ( crushed split ) Willing use nonhormonal method contraception patient reproductive potential Primary health care provider home location Hypercortisolism due Cushing 's disease . Type 1 diabetes mellitus HbA1c ≥9.5 % Screening Body weight &lt; 25 kg Use certain medication CYP3A substrates narrow therapeutic range , simvastatin , lovastatin , cyclosporine , dihydroergotamine , ergotamine , fentanyl , pimozide , quinidine , sirolimus , tacrolimus 4 week prior start study drug . Use medication also prohibit 2 week end dose . Use certain medication strong CYP3A inhibitor itraconazole , nefazodone , ritonavir , nelfinavir , indinavir , atazanavir , amprenavir , fosamprenavir , boceprevir , clarithromycin , conivaptan , lopinavir , mibefradil , posaconazole , saquinavir , telaprevir , telithromycin , voriconazole 2 week prior start study drug . Use medication also prohibit 2 week end dose . Grapefruit grapefruit juice , well grapefruitrelated fruit juice ( e.g . Seville orange , pomelo ) , prohibit time frame . Use certain medication strong inducer CYP3A rifampin , rifabutin , rifapentine , phenobarbital , phenytoin , carbamazepine , St. John 's wort 2 week prior start study drug . Use medication also prohibit 2 week end dose . Use medication use treat hypercortisolism duration indicate prior Day 1 . Use medication also prohibit end study 4 week follow visit . steroidogenesis inhibitor ketoconazole , metyrapone : 4 week cabergoline , bromocriptine , somatostatin analog octreotide , lanreotide , pasireotide long act formulation : 8 week ( immediate release formulation : 2 week ) mitotane : 8 week Use systemic glucocorticoid medication begin 1 month prior screen anticipate use medication except treatment adrenal insufficiency . Use glucocorticoid medication prohibit study end study 4 week study visit . Inflammatory , rheumatological , proliferative disorder ( ) would anticipate worsen glucocorticoid blockade ( e.g . inflammatory bowel disease , rheumatoid arthritis , psoriasis , etc. ) . Uncontrolled hypo hyperthyroidism . Uncorrected hypokalemia ( &lt; 3.5 mEq/L ) . The screening period may use correct hypokalemia prior start study drug . Use potassium and/or mineralocorticoid antagonist permit study . QTc ≥450 msec Screening electrocardiogram Unexplained vaginal bleeding female and/or history endometrial pathology . Positive pregnancy test female .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Cushing 's disease</keyword>
	<keyword>Mifepristone</keyword>
	<keyword>Cushing 's syndrome</keyword>
	<keyword>Pharmacokinetic-pharmacodynamic</keyword>
	<keyword>Child/pediatric population</keyword>
	<keyword>Safety-efficacy</keyword>
</DOC>